Last reviewed · How we verify
Placebo Spiriva capsule
Placebo Spiriva capsule is a Small molecule drug developed by Orion Corporation, Orion Pharma. It is currently FDA-approved for Clinical trial control for COPD and asthma studies. Also known as: Tiotropium Bromide, Tiotropium 18 µg, LAMA, tiotropium bromide.
This is a placebo formulation with no active pharmacological mechanism.
This is a placebo formulation with no active pharmacological mechanism. Used for Clinical trial control for COPD and asthma studies.
At a glance
| Generic name | Placebo Spiriva capsule |
|---|---|
| Also known as | Tiotropium Bromide, Tiotropium 18 µg, LAMA, tiotropium bromide |
| Sponsor | Orion Corporation, Orion Pharma |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
A placebo Spiriva capsule contains no active tiotropium or other therapeutic agent. It is used as a control in clinical trials to measure the effect of the active Spiriva formulation (tiotropium, a long-acting anticholinergic bronchodilator) against baseline or non-specific effects. Any observed benefit would be attributable to placebo response rather than drug mechanism.
Approved indications
- Clinical trial control for COPD and asthma studies
Common side effects
Key clinical trials
- Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- Tiotropium/Salmeterol Inhalation Powder in COPD (PHASE3)
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease (PHASE2)
- Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration (PHASE1, PHASE2)
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Spiriva capsule CI brief — competitive landscape report
- Placebo Spiriva capsule updates RSS · CI watch RSS
- Orion Corporation, Orion Pharma portfolio CI
Frequently asked questions about Placebo Spiriva capsule
What is Placebo Spiriva capsule?
How does Placebo Spiriva capsule work?
What is Placebo Spiriva capsule used for?
Who makes Placebo Spiriva capsule?
Is Placebo Spiriva capsule also known as anything else?
What development phase is Placebo Spiriva capsule in?
Related
- Manufacturer: Orion Corporation, Orion Pharma — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Clinical trial control for COPD and asthma studies
- Also known as: Tiotropium Bromide, Tiotropium 18 µg, LAMA, tiotropium bromide
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing